
Micro-Series | Part 4 | DLL3 in EP-NEC: A New Therapeutic Target Comes Into Focus
Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispec





